Dominari (DOMH) Competitors $5.26 +0.02 (+0.38%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. VNDA, LXRX, CDXS, ACHV, AGEN, SGMO, IRWD, FBIO, CRIS, and SABSShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Codexis (CDXS), Achieve Life Sciences (ACHV), Agenus (AGEN), Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Fortress Biotech (FBIO), Curis (CRIS), and SAB Biotherapeutics (SABS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Vanda Pharmaceuticals Lexicon Pharmaceuticals Codexis Achieve Life Sciences Agenus Sangamo Therapeutics Ironwood Pharmaceuticals Fortress Biotech Curis SAB Biotherapeutics Dominari (NASDAQ:DOMH) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking. Does the media refer more to DOMH or VNDA? In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Dominari. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 1 mentions for Dominari. Dominari's average media sentiment score of 1.87 beat Vanda Pharmaceuticals' score of 1.11 indicating that Dominari is being referred to more favorably in the media. Company Overall Sentiment Dominari Very Positive Vanda Pharmaceuticals Positive Do analysts rate DOMH or VNDA? Vanda Pharmaceuticals has a consensus target price of $16.50, indicating a potential upside of 256.37%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is DOMH or VNDA more profitable? Vanda Pharmaceuticals has a net margin of -9.51% compared to Dominari's net margin of -180.22%. Vanda Pharmaceuticals' return on equity of -3.49% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Dominari-180.22% -32.89% -29.47% Vanda Pharmaceuticals -9.51%-3.49%-2.90% Which has more volatility & risk, DOMH or VNDA? Dominari has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Which has preferable earnings & valuation, DOMH or VNDA? Vanda Pharmaceuticals has higher revenue and earnings than Dominari. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDominari$24.89M3.09-$22.88M-$4.50-1.17Vanda Pharmaceuticals$201.35M1.36-$18.90M-$0.75-6.17 Does the MarketBeat Community favor DOMH or VNDA? Vanda Pharmaceuticals received 546 more outperform votes than Dominari when rated by MarketBeat users. Likewise, 66.42% of users gave Vanda Pharmaceuticals an outperform vote while only 0.00% of users gave Dominari an outperform vote. CompanyUnderperformOutperformDominariOutperform VotesNo VotesUnderperform Votes1100.00% Vanda PharmaceuticalsOutperform Votes54666.42% Underperform Votes27633.58% Do institutionals & insiders have more ownership in DOMH or VNDA? 42.5% of Dominari shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 33.0% of Dominari shares are owned by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryVanda Pharmaceuticals beats Dominari on 15 of the 19 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariSecurity brokers & dealers IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.03M$33.44B$5.61B$8.62BDividend YieldN/A2.61%5.28%4.18%P/E Ratio-1.3616.0227.2619.97Price / Sales3.096.10412.06157.64Price / CashN/A22.5338.2534.64Price / Book0.532.987.064.69Net Income-$22.88M$1.49B$3.24B$248.14M7 Day Performance8.23%1.25%2.56%2.39%1 Month Performance-10.39%1.58%8.75%6.06%1 Year Performance144.65%36.94%31.30%13.57% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari1.6062 of 5 stars$5.26+0.4%N/A+140.4%$77.03M$24.89M-1.364Positive NewsVNDAVanda Pharmaceuticals4.7017 of 5 stars$4.30-0.9%$16.50+283.7%-23.5%$253.42M$201.35M-13.44290Positive NewsAnalyst RevisionLXRXLexicon Pharmaceuticals2.6889 of 5 stars$0.62-0.8%$3.67+489.9%-63.6%$224.70M$31.21M-0.83140Positive NewsCDXSCodexis3.9572 of 5 stars$2.25-2.2%$11.00+388.9%-28.9%$186.40M$49.82M-2.59250Positive NewsAnalyst RevisionACHVAchieve Life Sciences2.4075 of 5 stars$3.90+8.9%$14.33+267.5%-32.1%$135.27MN/A-3.4520High Trading VolumeAGENAgenus4.2182 of 5 stars$4.13+20.4%$9.00+117.9%-69.2%$113.23M$99.52M-0.37440Gap DownHigh Trading VolumeSGMOSangamo Therapeutics2.2128 of 5 stars$0.47+1.7%$4.50+851.6%-14.6%$108.42M$63.76M-0.63480Positive NewsGap DownIRWDIronwood Pharmaceuticals4.53 of 5 stars$0.62+3.5%$4.78+671.5%-88.5%$100.33M$317.68M-20.67220Gap UpFBIOFortress Biotech2.623 of 5 stars$1.84-2.6%$21.00+1,041.3%+6.6%$54.41M$57.78M-0.60170News CoverageNegative NewsStock SplitGap DownCRISCuris2.8715 of 5 stars$2.44-0.8%$17.00+596.7%-67.4%$25.53M$11.20M-0.3160News CoveragePositive NewsAnalyst RevisionGap UpSABSSAB Biotherapeutics3.7803 of 5 stars$1.92-0.5%$12.20+535.4%-44.5%$17.84M$2.24M-0.52140Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Vanda Pharmaceuticals Competitors Lexicon Pharmaceuticals Competitors Codexis Competitors Achieve Life Sciences Competitors Agenus Competitors Sangamo Therapeutics Competitors Ironwood Pharmaceuticals Competitors Fortress Biotech Competitors Curis Competitors SAB Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DOMH Stock Free DOMH Stock Alerts